Mo 2017.

Methods	Study design: Randomised clinical trial Study duration: May 2011 to May 2013 Duration of follow‐up: 3 years Setting: Hospital
Participants	Inclusion criteria: Diagnosed as primary liver cancer; aged ≥ 18 years; with liver function of Child‐Pugh A or B; unsuitable for resection or unwilling to accept surgery; abnormal haematopoietic function; no portal vein tumour thrombus; no extrahepatic metastasis. Exclusion criteria: Intrahepatic dissemination; huge liver cancer with intrahepatic or extrahepatic metastasis; with liver, cardiac, or kidney function damage; with the liver function of Child‐Pugh Class C; inadequate haematopoietic function; with systematic infection; allergic to contrast agent Male (n/total): TACE + RFA: 39/61; TACE alone: 35/56 Child‐Pugh Class (patients): Class A: TACE + RFA: 28; TACE: 20 Class B: TACE + RFA: 33; TACE: 36
Interventions	TACE + RFA group (n = 61): TACE: Chemotherapeutic drugs: theprubicin, 5‐fluorouracil, and oxaliplatin RFA: The interval between TACE and RFA was 2‐4 weeks. CT/Ultrasound‐guided RFA, with the ablation margin of 5‐10 mm TACE group (n = 56): Chemotherapeutic drugs: theprubicin, 5‐fluorouracil, and oxaliplatin. A total of 1‐3 sessions of TACE, with an interval of 1‐2 months
Outcomes	Serum level of AFP, VEGF, and CA‐199 Tumour response, according to the mRECIST criteria 1‐, 2‐, and 3‐year survival rates
Notes	Country of study: China Source of funding: None There was insufficient information available to satisfactorily determine the method of randomisation and the study data could not be verified. We have attempted to contact the study authors for more information, but so far, we have not been successful in doing this.